What Exo Therapeutics does

Exo Therapeutics is a preclinical, privately held small molecule drug discovery company founded in 2020 and headquartered in Cambridge, Massachusetts. The company is built on research from the laboratories of David Liu (Broad Institute / Harvard / HHMI) and Alan Saghatelian (Salk Institute), focusing on a class of binding sites — called exosites — that are distal, allosteric pockets on enzymes. Its proprietary ExoSight™ platform is used to identify and drug these exosites in order to selectively modulate enzyme activity for therapeutic effect, with a stated goal of targeting proteins previously considered undruggable.

The company has validated four initial targets and is advancing them toward the clinic. Its lead program, EXO-TBKi, is a TBK1 inhibitor being developed for autoimmune disease; the company has also disclosed additional programs in oncology and inflammation. It has presented preclinical data at major scientific forums including FOCIS 2024 and ACR Convergence 2024, signaling continued IND-enabling progress. As a pre-revenue biotech, the company does not yet sell products; its intended business model is to advance discovery and early development internally and then monetize assets through licensing or partnership agreements with larger pharmaceutical companies for later-stage clinical development and commercialization. To date the company has raised approximately $103M in venture funding (a $25M Series A in December 2020 and a $78M Series B in October 2021 led by Nextech Invest).

Name

Exo Therapeutics

Legal name

Exo Therapeutics, Inc.

Website

https://exo-therapeutics.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Exo Therapeutics is a preclinical biotech using its ExoSight™ platform to discover small molecule drugs that bind exosites on enzymes, advancing a pipeline in autoimmune, oncology, and inflammation disease areas.

Ownership category

akta.pro rank

Product category

Small Molecule Drug Discovery

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)

akta.pro primary industry

Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)

akta.pro secondary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Small molecule drugs
• Drug discovery platform
• Exosite targeting
• Enzyme inhibitors
• Precision oncology therapeutics

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Pharmaceutical Licensing and Partnership: Pre-revenue biotech company. Plans to advance drug candidates in oncology and inflammation toward clinical trials. Revenue model will likely involve licensing deals and partnerships with larger pharmaceutical companies for development and commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Exo Therapeutics is a small molecule drug discovery and development company that uses its proprietary ExoSight™ platform to identify exosites (distal, unique binding pockets on enzymes) and design selective small molecule drug candidates that modulate enzyme activity with precision and potency. Its initial therapeutic programs focus on oncology and inflammation, with a lead TBK1 exosite inhibitor program (EXO-TBKi) advancing toward the clinic for autoimmune diseases.

Product overview

Exo Therapeutics is a small molecule drug discovery and development company built on its proprietary ExoSight™ platform technology. The ExoSight platform enables the discovery of exosite-targeted small molecule drugs by identifying distal and unique binding pockets that modulate enzyme activity for precise therapeutic effects. The company's pipeline includes its lead TBK1 exosite inhibitor program (EXO-TBKi) targeting autoimmune diseases, along with additional programs in oncology and inflammation. Founded on groundbreaking research from the labs of David Liu and Alan Saghatelian at Harvard and Salk Institute, the company leverages its platform to address traditionally intractable drug targets.

Differentiator

Problem solved

Functional benefit

Products and services

• ExoSight™ Platform A comprehensive proprietary platform technology that identifies exosites (distal, unique binding pockets on enzymes that modulate enzyme activity) and systematizes discovery of novel exosite-targeted small molecule drugs across multiple enzyme classes, expanding the universe of druggable targets for precision medicine applications in oncology and inflammation.
• EXO-TBKi (TBK1 Exosite Inhibitor Program) Novel exosite inhibitors of TANK Binding Kinase 1 (TBK1) designed to selectively disrupt pathological STING-mediated TBK1 activation for the treatment of autoimmune diseases; preclinical data demonstrate selective disruption of STING-mediated TBK1 activation without affecting broader pathway signaling.
• Oncology and Inflammation Pipeline Programs Proprietary drug candidate programs initially focused in oncology and inflammation; four initial targets are successfully validated and advancing through the pipeline toward the clinic, leveraging the ExoSight platform's exosite-targeting approach across multiple enzyme classes.

Quantifiable outcome

• All four initial targets successfully validated
• +1 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Salk Institute for Biological StudiescoreStrategic or Co-development PartnerAcademic institution of Co-Founder Alan Saghatelian, PhD. Exo's scientific approach is based on research from the labs of David Liu and Alan Saghatelian.
• Broad InstitutecoreStrategic or Co-development PartnerAcademic institution of Co-Founder David Liu, PhD. Exo's foundational science originates from research at the Broad Institute labs.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Revolution Medicines: Revolution Medicines is a clinical-stage oncology biotech targeting difficult-to-drug targets (RAS, etc.) with proprietary tri-complex technology. Comparable to Exo as a small-molecule platform company pursuing undruggable oncology targets with novel binding mechanisms.
• Frontier Medicines: Frontier Medicines develops precision medicines against previously undruggable targets using chemoproteomics and covalent chemistry. Comparable to Exo in targeting hard-to-drug proteins with a platform-enabled discovery engine focused on oncology and inflammation.
• Morphic Holding: Morphic is developing oral integrin therapeutics based on proprietary insights into protein conformational change. Comparable to Exo as a small-molecule platform targeting difficult protein-binding pockets with a structurally-driven discovery approach in inflammation and related indications.
• Relay Therapeutics: Relay Therapeutics uses motion-based structural biology and computational chemistry to design precision medicines against previously undruggable targets. Comparable to Exo in leveraging structural/physical biology to expand druggable space in oncology.
• HotSpot Therapeutics: HotSpot Therapeutics is the closest analog to Exo — a biotech that discovers allosteric/exosite-binding small molecule drugs to modulate disease-driving proteins. Both companies share a near-identical scientific thesis (targeting distal regulatory pockets on enzymes), platform-drug discovery model, and focus on previously undruggable targets.

Emerging players

• Kymera Therapeutics: Kymera develops targeted protein degraders (Pegasus platform) against previously undruggable disease-driving proteins. Comparable to Exo in pursuing novel mechanisms to drug historically inaccessible targets in inflammation and oncology.
• Schrödinger, Inc. Schrödinger operates a physics-based computational platform for small-molecule drug discovery and has internal pipeline programs. Comparable to Exo as a platform-driven small-molecule discovery company, though Schrödinger's primary revenue comes from software licensing rather than internal asset development.
• Recursion Pharmaceuticals: Recursion applies AI/high-throughput biology to discover novel small molecules at scale across multiple therapeutic areas. Comparable to Exo as a platform-driven biotech attempting to expand the addressable target space through a differentiated discovery engine.
• Arvinas: Arvinas pioneered targeted protein degradation (PROTAC) to drug previously undruggable targets. Comparable to Exo in pioneering a new small-molecule mechanism to address intractable proteins, though Arvinas is more clinically advanced and degradation-based rather than exosite-based.
• Foghorn Therapeutics: Foghorn is a platform-driven biotech developing medicines against chromatin regulatory targets across oncology. Comparable to Exo as a platform-led biotech targeting previously undruggable protein classes with novel small-molecule chemistry.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xtwitter.com/ExoTherapeutics
• LinkedInlinkedin.com/company/exorx

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds2 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Exo Therapeutics